MolecuLight's Profound Impact on Wound Healing Highlighted in Breaking Clinical Research
Published on 08/07/2025 at 18:04 | prnewswire.co.uk
is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.
For sales, media or other inquiries or further information, please contact: Hunter Zudans, Director of Marketing, MolecuLight Inc., T. +1.484.682.7580, hzudans@moleculight.com, www.moleculight.com
View original content:https://www.prnewswire.co.uk/news-releases/moleculights-profound-impact-on-wound-healing-highlighted-in-breaking-clinical-research-302213795.html
en | boerse | 67983887 |
